Arena Pharmaceuticals — Corporate Update (September 2020)
13 slides from Arena Pharmaceuticals's corporate update, Sep 23, 2020
Slide 1: Etrasimod IBD Program Update
September 2020 Etrasimod IBD Program Update Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements September 2020 • This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about Arena’s business, catalysts, value, our investigative stage drug candidates, including with respect to their potential (inclu
Slide 3: Etrasimod: Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability
Etrasimod Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability Source: 1. Arena Quantitative Market Research, March 2018.; 2. Dahlhamer JM, et al. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169.; 3. UC & CD Disease Landscape & Forecast Reports. DRG. 2018 60-80% $24B+ Mark
Slide 4: Etrasimod Global Phase 3 Program in UC
Etrasimod Global Phase 3 Program in UC Overview of Registration Program Moderately to Severely Active UC Endpoints Primary Endpoint Week 12, week 52 clinical remission (modified Mayo Clinic score) Primary Endpoint Week 12 clinical remission (modified Mayo Clinic score) 52-Week Treat-through Trial 12
Slide 5: ELEVATE UC Program On Track To Readout Q4 2021
ELEVATE UC Program On Track To Readout Q4 2021 ELEVATE UC 52 enrollment remains on track with completion of enrollment expected by end of Q4 2020, with ELEVATE UC Program topline data readout scheduled for Q4 2021 First patient dosed in ELEVATE UC 12 study confirms that the ELEVATE UC registrational
Slide 6: Feedback From Stakeholders Has Identified a Significant Unmet Need in the UC Market
Feedback From Stakeholders Has Identified a Significant Unmet Need in the UC Market Convenient Delivery Oral therapy with comparable efficacy to current biologics Durable Response Replace long-term use of anti-TNFs, which can lose effectiveness Trusted Option Beyond 5-ASA Safe, oral step-up therapy
Slide 7: Market Research Supports Etrasimod as Potential Market Leader in UC Market
Source: Arena data on file. Market Research Supports Etrasimod as Potential Market Leader in UC Market Future Preference „ Expanding Oral Market ¢ Novel Oral ¢ Biologics 81% S1P vs. JAK ¢ S1P Modulator ¢ JAK Inhibitor Etrasimod vs. Ozanimod ¢ Etrasimod ¢ Ozanimod 64% 32% September 2020 •
Slide 8: Broad Group of Sub-Optimally Controlled Patients Eligible for Advanced Therapy
Broad Group of Sub-Optimally Controlled Patients Eligible for Advanced Therapy, But Reluctant Due to Risk/Benefit Profile Symptom Worsening Aminosalicylate Corticosteroids / Immunosupressives Biologics Cyclosporine /JAKs Tacrolimus / Surgery Sub-optimal control on conventional Tx Advanced Tx Patient
Slide 9: GLADIATOR-UC – Expected to Initiate Early 2021
GLADIATOR-UC – Expected to Initiate Early 2021 Subject Screening: During ELEVATE UC enrollment period After ELEVATE UC completes enrollment MMS 4-9, with ES ≥ 2 & RB ≥1 MMS 4-6, with ES ≥ 1 MMS 4-6, with ES ≥ 1 September 2020 • MMS: Modified Mayo Score; ES: Endoscopic Score; RB: Rectal Bleeding
Slide 10: Focus on Patients Sub-Optimally Controlled on Conventional Tx
Focus on Patients Sub-Optimally Controlled on Conventional Tx Symptom Worsening Aminosalicylate Corticosteroids / Immunosupressives Biologics Cyclosporine /JAKs Tacrolimus / Surgery Sub-optimal control on conventional Tx Advanced Tx Patients Maintained Conventional Tx Patients September 2020 •
Slide 11: Etrasimod Ph 2/3 Program in Crohn's Disease
*Subjects who do not meet response criteria at Week 14 will enter a 6-week Extended Induction Period † Sub-studies 2, 3 and phase 3 induction will begin with both 2 and 3 mg doses until dose selection is determined at the completion of Sub-Study 1 ‡ Primary efficacy endpoints for Sub-study 2 and Pha
Slide 12: Catalyst Horizon
Catalyst Horizon New IND(s) APD418 Ph 1 Data Etrasimod AA Ph 2 Data Etrasimod ADVISE (AD) Ph 2b Data Etrasimod ELEVATE UC 52 Ph 3 Data APD418 Ph 2a Data H2 2020 H1 2021 H2 2021 H1 2022 H2 2022 COVID-19 IMPACTED / TIMELINES DEPENDENT ! Etrasimod CD Ph 3 Data Etrasimod CULTIVATE (CD) Ph 2 Data Olorina
Slide 13: Arena Pharmaceuticals
ARENA PHARMACEUTICALS Nasdaq: ARNA
Arena Pharmaceuticals — Corporate Update (September 2020) on 6ix